What Oncolytics Biotech Inc.’s FDA meeting means for pelareorep commercialization
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Pharma & Biotech
Pharma & Biotech
Cognition Therapeutics advances regulatory strategy for zervimesine in an underserved neurodegenerative disease
Cognition Therapeutics aligns with FDA on zervimesine Phase 2b plans. Discover what this means for dementia with Lewy bodies drug development.